Recombinant human interferon alpha-2b biosimilar - Tianjin Sinobioway Biomedicine

Drug Profile

Recombinant human interferon alpha-2b biosimilar - Tianjin Sinobioway Biomedicine

Alternative Names: Alfaron; Jaferon; rhIFNα2b

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tianjin Sinobioway Biomedicine
  • Developer Beijing Ditan Hospital Capital Medical University; Tianjin Sinobioway Biomedicine
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Condylomata acuminata; Hepatitis A; Hepatitis B; Herpes simplex virus infections; Leukaemia
  • Phase I Coxsackievirus infections

Most Recent Events

  • 07 Nov 2017 Launched for Condylomata acuminata in China (Topical) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)
  • 07 Nov 2017 Launched for Hepatitis A in China (Injection) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)
  • 07 Nov 2017 Launched for Hepatitis B in China (Injection) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top